| Project/Area Number |
26462222
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
川端 信司 大阪医科大学, 医学部, 講師 (20340549)
|
|---|
| Research Collaborator |
NONOGUCHI Naosuke
TOHO Taichiro
TSUJI Yuichiro
FUKUMURA Masao
YOSHIKAWA Masashi
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 放射線壊死 / ベバシズマブ / 神経膠腫 / 髄膜腫 / VEGF / bevacizumab / glioma / glioblastoma / radiation / radiation necrosis / meningioma |
|---|
| Outline of Final Research Achievements |
The aim of this study was to concur radiation necrosis of the brain. In a laboratory study, an optical radiation dose for formation of radiation necrosis was clarified in rats. Radiation necrosis stably appeared 6 months after 65 Gy of a single fraction. In the next study, key molecules for radiation necrosis will be elucidated using this model. In a clinical study, bevacizumab suppressed radiation necrosis, but not tumor tissue in previously irradiated meningioma. Recurrent meningioma could be distinguished from radiation necrosis by administration of bevacizumab. In radiation necrosis, efficacy of bevacizumab lasted 6 months after completion of bevacizumab therapy. And we reported pathological review of brain radiation necrosis.
|
